ArriVent BioPharma (AVBP) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), ArriVent BioPharma had return on equity of -58.9% (down from -39.4%), debt-to-equity of 0.00 (down from 0.00), a current ratio of 12.83 (down from 13.14) and return on assets of -36.5% (down from -26.9%). A current ratio of 12.83 means current assets exceed current liabilities.

ArriVent BioPharma Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Valuation Ratios
P/B Ratio	2.70	3.48	-	-	-
Price/Tangible Book	2.70	3.48	-	-	-
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)	-58.88%	-39.36%	-42.57%	-34.22%	-
Return on Assets (ROA)	-36.49%	-26.91%	-26.95%	-20.42%	-
Return on Capital Employed (ROCE)	-57.80%	-36.60%	-49.20%	-21.20%	-28.10%
Leverage & Solvency Ratios
Debt/Equity	0.00	0.00	0.00	0.00	-
Liquidity Ratios
Current Ratio	12.83	13.14	13.76	21.84	23.63
Quick Ratio	12.06	12.70	13.00	19.60	20.64
Efficiency Ratios
Yield & Distribution Ratios
Earnings Yield	-20.02%	-8.97%	-	-	-
Buyback Yield	-22.22%	-1369.88%	-67.64%	-79.57%	-

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About ArriVent BioPharma Financial Ratios

What is ArriVent BioPharma's return on equity?

ArriVent BioPharma's return on equity (ROE) was -58.9% for fiscal 2025 (period ended Dec 31, 2025). It was -39.4% a year earlier.

What is ArriVent BioPharma's debt-to-equity ratio?

ArriVent BioPharma's debt-to-equity ratio was 0.00 for fiscal 2025 (period ended Dec 31, 2025). It was 0.00 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition